IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Aurobindo and Celon Laboratories form generics JV to cater US and Europe

9:53 AM MST | December 10, 2013 | Natasha Alperowicz

Celon Laboratories (Hyderabad, India) said on Monday that it has entered into an agreement with Aurobindo Pharma (Hyderabad) to form a joint venture to develop, manufacture, and sell hormonal and oncology generic formulations for the US and European markets. A special-purpose vehicle company, Eugia Pharma Specialties, will be formed and in which Aurobindo will hold 60% and Celon 40%. The companies will invest a combined 1.8–2.0 billion Indian rupees ($29.5–32.8 million) in the jv over the next two to three years. Aurobindo, in August, agreed to...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa